TG Therapeutics, Inc.

TGTX

US88322Q1085

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-15 pm EDT			5-day change	1st Jan Change
17.72 ^USD	-1.34%		+3.50%	+3.75%

May. 01	Wall Street Set to Open Lower Ahead of Fed Rate Decision; Private Employment Figures Top Forecasts	MT
May. 01	Transcript : TG Therapeutics, Inc., Q1 2024 Earnings Call, May 01, 2024

Manhattan Pharmaceuticals, Inc. has Changed its Name to TG Therapeutics, Inc

April 22, 2012 at 03:44 pm EDT

Manhattan Pharmaceuticals, Inc. changed its name to TG Therapeutics, Inc.

Latest news about TG Therapeutics, Inc.

Wall Street Set to Open Lower Ahead of Fed Rate Decision; Private Employment Figures Top Forecasts	May. 01	MT
Transcript : TG Therapeutics, Inc., Q1 2024 Earnings Call, May 01, 2024	May. 01
Earnings Flash (TGTX) TG THERAPEUTICS Reports Q1 Revenue $63.5M, vs. Street Est of $54.6M	May. 01	MT
TG Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 01	CI
North American Morning Briefing : Investors Brace -2-	Apr. 29	DJ
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	Apr. 18	MT
Sector Update: Health Care	Apr. 18	MT
TG Therapeutics Wins Veterans Affairs Contract for Multiple Sclerosis Drug Briumvi	Apr. 18	MT
Tg Therapeutics, Inc. Awards National Contract by the Department of Veterans Affairs for Briumvi as the Preferred Anti-Cd20 for Relapsing Forms of Multiple Sclerosis	Apr. 18	CI
Tg Therapeutics Insider Sold Shares Worth $351,340, According to a Recent SEC Filing	Mar. 13	MT
TG Therapeutics Says Updated Data in Briumvi Study Shows Manageable Safety, Tolerability Profile	Mar. 01	MT
Goldman Sachs Raises Price Target on TG Therapeutics to $13 From $12, Maintains Neutral Rating	Feb. 29	MT
Sector Update: Health Care Stocks Softer Wednesday Afternoon	Feb. 28	MT
TG Therapeutics Narrows Q4 Net Loss, Revenue Jumps; Shares Surge	Feb. 28	MT
TG Therapeutics Narrows Q4 Net Loss, Revenue Jumps; Shares Surging in Pre-Trade	Feb. 28	MT
Transcript : TG Therapeutics, Inc., Q4 2023 Earnings Call, Feb 28, 2024	Feb. 28
Earnings Flash (TGTX) TG THERAPEUTICS Posts Q4 Revenue $44M, vs. Street Est of $40.1M	Feb. 28	MT
TG Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
TG Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 28	CI
TG Therapeutics to Receive $12.5 Million Milestone Payment for Launch of Briumvi in Europe	Feb. 26	MT
Precision BioSciences, Inc. announced that it expects to receive funding from TG Therapeutics, Inc.	Feb. 11	CI
B. Riley Adjusts Price Target on TG Therapeutics to $29 From $24, Maintains Buy Rating	Feb. 05	MT
HC Wainwright Adjusts TG Therapeutics Price Target to $45 From $41, Maintains Buy Rating	Jan. 11	MT
Sector Update: Health Care Stocks Higher in Afternoon Trading	Jan. 10	MT
TG Therapeutics Shares Fall After Reporting Net Product Preliminary Revenues for Briumvi; Provides 2024 Targets	Jan. 10	MT

TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Brutonâs tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.

Sector

Biotechnology & Medical Research

Calendar

2024-06-14 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for TG Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

17.72 USD

Average target price

31.5 USD

Spread / Average Target

+77.77%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
TG THERAPEUTICS, INC.	+3.75%	2.54B
MODERNA, INC.	+29.77%	49.46B
IQVIA HOLDINGS INC.	+1.00%	42.58B
LONZA GROUP AG	+49.45%	42.49B
CELLTRION, INC.	-5.26%	29.09B
ICON PUBLIC LIMITED COMPANY	+13.68%	26.61B
ALNYLAM PHARMACEUTICALS, INC.	-22.99%	18.64B
BIO-TECHNE CORPORATION	+8.22%	13.16B
MEDPACE HOLDINGS, INC.	+32.41%	12.55B
UNITED THERAPEUTICS CORPORATION	+24.01%	12.1B

Other Biotechnology & Medical Research

TG Therapeutics, Inc.

Equities

TGTX

US88322Q1085

Biotechnology & Medical Research

Manhattan Pharmaceuticals, Inc. has Changed its Name to TG Therapeutics, Inc

Latest news about TG Therapeutics, Inc.

Chart TG Therapeutics, Inc.

Company Profile

Income Statement Evolution

Ratings for TG Therapeutics, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research